#Sweden #Immunotherapy #Stockholm #Pixelgen #Karolinska

A Groundbreaking Collaboration in Cancer Research

Pixelgen Technologies has announced an exciting new partnership with the renowned Andreas Lundqvist research group at the Karolinska Institutet. This collaboration aims to uncover novel biomarkers that can significantly enhance cancer immunotherapy efforts. By employing Pixelgen's Proximity Network Assay (PNA), the research will focus on understanding the spatial distribution and prevalence of cell surface proteins in patients suffering from non-small cell lung cancer, particularly those undergoing treatment with immune checkpoint inhibitors.

The Promise of Proximity Network Assay (PNA)

The Proximity Network Assay is an innovative technology that offers a fresh perspective on the organization and interactions of proteins at the cellular level. According to Professor Lundqvist, this technique holds significant potential for illuminating the intricacies of how cell surface proteins work together, which could pave the way for identifying new biomarkers relevant to immune checkpoint inhibition responses. Unlike existing tools that primarily assess protein abundance, PNA introduces a critical understanding of spatial protein organization, which could be invaluable in tailoring treatment strategies for patients.

Combining Expertise to Drive Innovation

This collaboration seamlessly merges the foundational expertise in tumor immunology and cell biology from Professor Lundqvist's team with Pixelgen's advanced technology and experience in cell surface protein interactomics. The combined efforts are geared toward yielding results that the team hopes to submit for publication in a peer-reviewed scientific journal, thereby contributing to the broader field of cancer research.

"We are thrilled to partner with Professor Lundqvist's esteemed group, known for their significant contributions to tumor immunology, especially in immune escape and cell-based therapeutic advancements," stated Erik Pettersson, Pixelgen's Chief Business Development Officer. Pettersson added, "Our aim is to enhance our understanding of how interactions among single-cell proteins influence cancer progression and immunotherapy effectiveness. Ultimately, we hope to identify biomarkers that lead to the development of more effective immunotherapies for cancer patients."

Advancing Drug Discovery and Diagnostics

At the heart of this innovative approach is the Pixelgen Proxiome Kit, which leverages PNA to deliver nanoscale spatial analysis of immune cell proteins. The technology is not just limited to cancer research; it's poised to revolutionize drug discovery and diagnostics across various fields including immunology, immuno-oncology, hematology, and cell therapy. Researchers globally are eager to explore new avenues this technology opens for elucidating mechanisms of drug action and patient response.

About Pixelgen Technologies

Founded in 2020, Pixelgen Technologies AB is dedicated to advancing our understanding of biological processes at the molecular level. By focusing on the protein interactomics of single cells, the company has developed the patented PNA technology which allows for exceptionally detailed spatial analysis of immune cell proteins. The company offers a suite of products aimed at enhancing precision medicine and driving innovations in translational research, making it a key player in the future of cancer therapies.

As Pixelgen and Karolinska Institutet embark on this groundbreaking journey together, the scientific community watches with anticipation, hopeful for new insights that could transform cancer immunotherapy and improve outcomes for patients in need.